thromboplastin and Teratocarcinoma
thromboplastin has been researched along with Teratocarcinoma* in 2 studies
Other Studies
2 other study(ies) available for thromboplastin and Teratocarcinoma
Article | Year |
---|---|
Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides.
This study was performed to evaluate the mechanisms leading to tumor vessel occlusion by tissue factor-based drugs, which are used in vascular targeting approaches for the treatment of malignant tumors.. The effects of nontargeted soluble tissue factor were evaluated in vitro and in vivo. Tumor-bearing mice were treated with (1) the extracellular portion of tissue factor (soluble tissue factor), (2) low nontoxic doses of lipopolysaccharides, or (3) a combination thereof. The combination treatment showed the best effects and resulted in selective thrombosis of tumor vessels. On the basis of our data from subsequent in vitro analyses, including surface plasmon resonance measurements and endothelial cell based coagulation assays, we propose a model on how soluble tissue factor, although lacking its membrane anchor, can promote selective tumor vessel occlusion.. To our knowledge, this is the first report to describe the molecular mechanisms of coagulation induction by untargeted soluble tissue factor in vivo. Combination treatments including soluble tissue factor might represent an alternative vascular targeting approach for the treatment of malignant tumors. Topics: Animals; Blood Coagulation; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Embolization, Therapeutic; Enzyme Activation; Factor Xa; Humans; Lipopolysaccharides; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Mice, SCID; Peptide Fragments; Recombinant Proteins; Solubility; Surface Plasmon Resonance; Teratocarcinoma; Thromboplastin; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2003 |
Effect of tissue factor deficiency on mouse and tumor development.
Previous reports suggest that tissue factor (TF) may play an essential role in embryonic vascular development and tumor angiogenesis. To further examine this relationship, the morphology of fully developed TF-deficient embryos and the growth of TF-deficient teratomas and teratocarcinomas were analyzed. In a 129/Sv genetic background, TF null embryos do not survive beyond mid-gestation. In contrast, 14% of 129/Sv x C57BL/6 TF-deficient embryos escape this early mortality and survive to birth. On gross and microscopic inspection, these late gestation, TF-deficient embryos appear normal. The growth and vascularity of TF(+/+), TF(+/-), and TF(-/-) teratomas and teratocarcinomas are indistinguishable. Thus, tumor-derived TF is not required for tumor growth and angiogenesis and the combined data do not support an essential role for TF in embryonic vascular development. Topics: Animals; Embryonic and Fetal Development; Female; Gene Deletion; Gene Expression Regulation, Developmental; Male; Mice; Mice, Inbred C57BL; Pregnancy; Teratocarcinoma; Teratoma; Testicular Neoplasms; Thromboplastin | 1997 |